QualityStocksNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q1 Revenue Growth Driven by CDMO Contracts, Net Loss Narrows
Scinai Immunotherapeutics (NASDAQ: SCNI) reported first quarter 2025 financial results, posting $586K in revenue, up from zero in the prior-year…